The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-β2

British Journal of Cancer

Volumn 96, Issue 10, 2007, Pages 1560-1568

  Arslan, F ^a,b   Bosserhoff, A K ^a   Nickl Jockschat, T ^c   Doerfelt, A ^a   Bogdahn, U ^a   Hau, P ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF OSLO   (Norway)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

High grade glioma; Migration; TGF ; Versican

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GLYCOSAMINOGLYCAN; ISOPROTEIN; TRANSFORMING GROWTH FACTOR BETA2; VERSICAN;

ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GLIOMA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

CELL MOVEMENT; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; NEOPLASM INVASIVENESS; PROTEIN ISOFORMS; TRANSFORMING GROWTH FACTOR BETA2; TUMOR CELLS, CULTURED; VERSICANS;

EID: 34248599025     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603766     Document Type: Article

References (58)

1. Ang LC, Zhang Y, Cao L, Yang BL, Young B, Kiani C, Lee V, Allan K, Yang BB (1999) Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J Neuropathol Exp Neurol 58: 597-605
2. Arslan F, Doerfelt A, Bogdahn U, Hau P (2006) The regulatory role of transforming growth factor-{beta}2 in malignant glioma invasion via modulation of extracellular matrix. Proc Am Assoc Cancer Res 47: 3285 (abstract)
3. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG (2004) Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 36: 1046-1069
4. Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J, Martin R (1989) Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res 49: 5358-5363
5. Bouterfa H, Darlapp AR, Klein E, Pietsch T, Roosen K, Tonn JC (1999) Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. J Neurooncol 44: 23-33
6. Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M, Lamszus K (2003) Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 52: 1391-1399
7. Cattaruzza S, Schiappacassi M, Kimata K, Colombatti A, Perris R (2004) The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells. FASEB J 18: 779-781
8. Cattaruzza S, Schiappacassi M, Ljungberg-Rose A, Spessotto P, Perissinotto D, Morgelin M, Mucignat MT, Colombatti A, Perris R (2002) Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro. J Biol Chem 277: 47626-47635
9. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 425: 577-584
10. Dours-Zimmermann MT, Zimmermann DR (1994) A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J Biol Chem 269: 32992-32998
11. Dumont N, Arteaga CL (2003) Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 3: 531-536; doi:10.1016/S1535- 6108(03)00135-1
12. Fakhrai H, Mantil JC, Liu L, Nicholson GL, Murphy-Satter CS, Ruppert J, Shawler DL (2006) Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 13: 1052-1060
13. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M (2004) RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64: 7596-7603
14. Goldbrunner RH, Bernstein JJ, Tonn JC (1998) ECM-mediated glioma cell invasion. Microsc Res Tech 43: 250-257
15. Grauer O, Poschl P, Lohmeier A, Adema GJ, Bogdahn U (2006) Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2. J Neurooncol 82: 151 -161
16. Hau P, Kunz-Schughart LA, Rummele P, Arslan F, Dorfelt A, Koch H, Lohmeier A, Hirschmann B, Muller A, Bogdahn U, Bosserhoff AK (2006) Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas. J Neurooncol 77: 1-7
17. Held-Feindt J, Lutjohann B, Ungefroren H, Mehdorn HM, Mentlein R (2003) Interaction of transforming growth factor-beta (TGF-beta) and epidermal growth factor (EGF) in human glioma cells. J Neurooncol 63: 117-127
18. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W (1993) The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 78: 944-951
19. Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH, Bauer A, Blesch A, Bogdahn U (1996) Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65: 332-337
20. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111-1116
21. Kahari VM, Larjava H, Uitto J (1991) Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture. J Biol Chem 266: 10608-10615
22. Kern CB, Norris RA, Thompson RP, Argraves WS, Fairey SE, Reyes L, Hoffman S, Markwald RR, Mjaatvedt CH (2007) Versican proteolysis mediates myocardial regression during outflow tract development. Dev Dyn 236: 1157
23. Kern CB, Twal WO, Mjaatvedt CH, Fairey SE, Toole BP, Iruela-Arispe ML, Argraves WS (2006) Proteolytic cleavage of versican during cardiac cushion morphogenesis. Dev Dyn 235: 2238-2247
24. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, Salford LG, Sjogren HO, Widegren B (2000) Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89: 251-25826
25. Landolt RM, Vaughan L, Winterhalter KH, Zimmermann DR (1995) Versican is selectively expressed in embryonic tissues that act as barriers to neural crest cell migration and axon outgrowth. Development 121: 2303-2312
26. Lemire JM, Braun KR, Maurel P, Kaplan ED, Schwartz SM, Wight TN (1999) Versican/PG-M isoforms in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19: 1630-1639
27. Merzak A, McCrea S, Koocheckpour S, Pilkington GJ (1994) Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1. Br J Cancer 70: 199-203
28. Nakada M, Miyamori H, Kita D, Takahashi T, Yamashita J, Sato H, Miura R, Yamaguchi Y, Okada Y (2005) Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol (Berl) 110: 239-246
29. Nickl-Jockschat T, Arslan F, Doerfelt A, Bogdahn U, Bosserhoff A, Hau P (2007) An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas. Int J Oncol 30: 499-507
30. Nikitovic D, Zafiropoulos A, Katonis P, Tsatsakis A, Theocharis AD, Karamanos NK, Tzanakakis GN (2006) Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 58: 47-53
31. Pan JJ, Chang WJ, Barone TA, Plunkett RJ, Ostrow PT, Greenberg SJ (2006) Increased expression of TGF-beta1 reduces tumor growth of human U-87 glioblastoma cells in vivo. Cancer Immunol Immunother 55: 918-92734
32. Paulus W, Baur I, Huettner C, Schmausser B, Roggendorf W, Schlingensiepen KH, Brysch W (1995) Effects of transforming growth factor-beta 1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells. J Neuropathol Exp Neurol 54: 236-244
33. Platten M, Wick W, Weller M (2001) Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 52: 401-410
34. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M (2000) Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Upregulation of alpha(V)beta(3) integrin expression. Biochem Biophys Res Commun 268: 607- 611
35. Robbins JR, Evanko SP, Vogel KG (1997) Mechanical loading and TGF-beta regulate proteoglycan synthesis in tendon. Arch Biochem Biophys 342: 203-211
36. Russell DL, Doyle KM, Ochsner SA, Sandy JD, Richards JS (2003) Processing and localization of ADAMTS-1 and proteolytic cleavage of versican during cumulus matrix expansion and ovulation. J Biol Chem 278: 42330-42339
37. Sandy JD, Westling J, Kenagy RD, Iruela-Arispe ML, Verscharen C, Rodriguez-Mazaneque JC, Zimmermann DR, Lemire JM, Fischer JW, Wight TN, Clowes AW (2001) Versican V1 proteolysis in human aorta in vivo occurs at the Glu441- Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem 276: 13372-13378
38. Schmalfeldt M, Bandtlow CE, Dours-Zimmermann MT, Winterhalter KH, Zimmermann DR (2000) Brain derived versican V2 is a potent inhibitor of axonal growth. J Cell Sci 113: 807-816
39. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P (2006) Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine Growth Factor Rev 17: 129-139
40. Schonherr E, Jarvelainen HT, Sandell LJ, Wight TN (1991) Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem 266: 17640-17647
41. Serra M, Miquel L, Domenzain C, Docampo MJ, Fabra A, Wight TN, Bassols A (2005) V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential. Int J Cancer 14: 879-886
42. Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS, Wu Y, Lee V, Slingerland J, Dumont D, Yang BB (2005) The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell 16: 1330-1340; doi:10.1091/mbc.E04-04-0295
43. Shiou SR, Datta PK, Dhawan P, Law BK, Yingling JM, Dixon DA, Beauchamp RD (2006) Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta. J Biol Chem 281: 33971-33981
44. Somerville RP, Longpre JM, Jungers KA, Engle JM, Ross M, Evanko S, Wight TN, Leduc R, Apte SS (2003) Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1. J Biol Chem 278: 9503-9513
45. Spandidos DA, Kerr IB (1998) Elevated expression of the human ras oncogene family in premalignant and malignant tumours of the colorectum. Br J Cancer 49: 681-688
46. Touab M, Villena J, Barranco C, Arumi-Uria M, Bassols A (2002) Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 160: 549-557
47. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M (2004) SD-208, a novel transforming growth factor beta receptor I kinase inhibitor,inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64: 7954-7961
48. Venkatesan N, Roughley PJ, Ludwig MS (2002) Proteoglycan expression in bleomycin lung fibroblasts: role of transforming growth factor-beta(1) and interferon-gamma. Am J Physiol Lung Cell Mol Physiol 283: L806-L814
49. Wick W, Naumann U, Weller M (2006) Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr Pharm Des 12: 341-349
50. Wu Y, Chen L, Cao L, Sheng W, Yang BB (2004a) Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and beta1-integrin. J Cell Sci 117: 2227-2237
51. Wu Y, Sheng W, Chen L, Dong H, Lee V, Lu F, Wong CS, Lu WY, Yang BB (2004b) Versican V1 isoform induces neuronal differentiation and promotes neurite outgrowth. Mol Biol Cell 15: 2093-2104
52. Wu Y, Chen L, Zheng PS, Yang BB (2002) Beta 1-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J Biol Chem 277: 12294-12301
53. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB (2005) The interaction of versican with its binding partners. Cell Res 15: 483-494
54. Yamagata M, Kimata K (1994) Repression of a malignant cell-substratum adhesion phenotype by inhibiting the production of the anti-adhesive proteoglycan, PG-M/versican. J Cell Sci 107: 2581-2590
55. Yang BL, Zhang Y, Cao L, Yang BB (1999) Cell adhesion and proliferation mediated through the G1 domain of versican. J Cell Biochem 72: 210-220
56. Zhang Y, Cao L, Yang BL, Yang BB (1998) The G3 domain of versican enhances cell proliferation via epidermial growth factor-like motifs. J Biol Chem 273: 21342-21351
57. Zhao X, Russell P (2005) Versican splice variants in human trabecular meshwork and ciliary muscle. Mol Vis 11: 603-608
58. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, Yang BB (2004) Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 18: 754-756